CN102309506A - Application of drug composition in preparation of drugs for treating osteoporosis - Google Patents
Application of drug composition in preparation of drugs for treating osteoporosis Download PDFInfo
- Publication number
- CN102309506A CN102309506A CN2011101251677A CN201110125167A CN102309506A CN 102309506 A CN102309506 A CN 102309506A CN 2011101251677 A CN2011101251677 A CN 2011101251677A CN 201110125167 A CN201110125167 A CN 201110125167A CN 102309506 A CN102309506 A CN 102309506A
- Authority
- CN
- China
- Prior art keywords
- inorganic acid
- acid salt
- trivalent
- vanadium
- tetravalence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to application of a drug composition in preparation of drugs for treating osteoporosis, belonging to the field of chemical drugs. The drug composition comprises the following active ingredient: inorganic acid salt of trivalent V. The clinical research indicates that after being used, the drug does not have obvious toxic or side effect and has an obvious effect on treating osteoporosis. The invention provides a new option for treating osteoporosis, and the drug composition has broad market prospect.
Description
Technical field
The present invention relates to the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis, belong to the chemical medicine field.
Background technology
Osteoporosis (osteoporosis) is a kind of systemic osteopathia; It is characterized in that the bone amount descends and the fine structure of bone destroys; The fragility that shows as bone increases, thereby the danger of fracture greatly increases, even also fracture easily under slight wound or the atraumatic situation.Osteoporosis is a kind of chronic disease due to multifactor.Before fracture takes place, there is not special clinical manifestation usually.The women is more than the male for this disease, is common in postmenopausal women and old people.Along with the increase of China's aging population, the osteoporosis sickness rate is in ascendant trend, all is a health problem that merits attention in the China and even the whole world.
Vanadium is one of trace element necessary in the human body, and vanadium is extremely low at the intravital content of people, and insufficient total amount is 1 milligram in the body, mainly is distributed in internal organs, positions such as liver, kidney, thyroid especially, and content is also higher in the osseous tissue.Vanadium is merely 5% at the gastrointestinal absorbance, and its absorption site is mainly at upper digestive tract.About 95% vanadium combines with transferrins with ionic condition and carries in the blood, so vanadium and ferrum can interact in human body.Vanadium is a many-side in the intravital function of people, and the most approved vanadium lacks the research to goat and white mouse that performance comes from report in 1987, and the goat that vanadium lacks shows the abortion ratio increase and milk yield reduces.In the white mouse experiment, the vanadium shortage causes growth inhibited, and the reproduction function is weak, the ratio increase of thyroid weight and body weight and the variation of plasma thyroid hormones concentration.At present, still indeterminate for the research of human body vanadium deficiency disease.
Summary of the invention
Technical problem to be solved by this invention provides the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis
The present invention provides the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis, and wherein, described pharmaceutical composition comprises the inorganic acid salt of following active component: trivalent V.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of tetravalence V.
Wherein, better for the drug effect that makes medicine, the mol ratio of the inorganic acid salt of the inorganic acid salt of above-mentioned trivalent V and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.
Wherein, as preferred technical scheme, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the aforementioned pharmaceutical compositions and tetravalence V counts 0.9～1.1 with vanadium: 0.9～1.1.
Wherein, as most preferred technical scheme, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the aforementioned pharmaceutical compositions and tetravalence V is counted 1: 1 with vanadium.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of pentavalent V.Wherein, the content of vanadium of the inorganic acid salt of pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises proper inorganic acid, and wherein, said mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
The active component of aforementioned pharmaceutical compositions can be merely the inorganic acid salt of trivalent V.
Wherein, the active component of aforementioned pharmaceutical compositions can also be inorganic acid salt and the proper inorganic acid of trivalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of trivalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively trivalent V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively trivalent V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of trivalent V and the inorganic acid salt of tetravalence V.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of trivalent V, inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of trivalent V and tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the inorganic acid salt of the V in the aforementioned pharmaceutical compositions is preferably sulfate, chlorate or phosphate.Further, when V was trivalent, the inorganic acid salt of V was preferably VCl
3, VOCl, V
2(SO
4)
3, VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3When V was tetravalence, the inorganic acid salt of V was preferably: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was preferably VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Inventor of the present invention is through discovering that the vanadium cation that contains in the pharmaceutical composition of the present invention is a main active.Therefore, the present invention also provides the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis, and this pharmaceutical composition comprises following active component: the cation that contains trivalent vanadium; Wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2+
Further, cation that contains trivalent vanadium and the VO in the aforementioned pharmaceutical compositions
2+Mol ratio be preferably 0.5～1.5: 0.5～1.5.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio more preferably 0.9～1.1: 0.9～1.1.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio most preferably be 1: 1.
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2+Wherein, VO
2+Content is preferably cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.
Further, above-mentioned said active ingredient in pharmaceutical also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+Wherein, K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can be for containing the cation of trivalent vanadium, and wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+And contain the cation of trivalent vanadium, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation and the VO that contains trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, L
I+And/or Ge
4+, contain the cation and the VO of trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation, the VO that contains trivalent vanadium
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is V
O+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, contain the cation of trivalent vanadium, VO
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Wherein, above-mentioned K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.Above-mentioned VO
2 +Content is preferably cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio be preferably 0.5～1.5: 0.5～1.5.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio more preferably 0.9～1.1: 0.9～1.1.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio most preferably be 1: 1.
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Aforementioned pharmaceutical compositions can be the pharmaceutical dosage form of routine, and wherein, the dosage form of aforementioned pharmaceutical compositions is preferably transdermal formulation.Further, described transdermal formulation is preferably patch, varnish, liniment, aerosol, unguentum, solution or lotion.
When the dosage form of said medicine is lotion, when using, the patient can medicine of the present invention be added suitable quantity of water, and make the pH value of solution reach the acceptable faintly acid scope of human body; Soak then and use; General soak time 10～40min gets final product, and during immersion, soaks every day 1～6 time.
The cost that medicine of the present invention is compared commercially available similar medicine is lower, has alleviated patient's financial burden.Show through clinical research, use medicine of the present invention not see that obvious toxic and side effects is arranged, the effect of treatment osteoporosis is remarkable, can obviously improve bone density.The present invention has vast market prospect for the treatment of osteoporosis provides a kind of new selection.
The specific embodiment
The present invention provides the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis, and wherein, described pharmaceutical composition comprises the inorganic acid salt of following active component: trivalent V.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of tetravalence V.
Wherein, better for the drug effect that makes medicine, the mol ratio of the inorganic acid salt of the inorganic acid salt of above-mentioned trivalent V and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.
Wherein, as preferred technical scheme, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the aforementioned pharmaceutical compositions and tetravalence V counts 0.9～1.1 with vanadium: 0.9～1.1.
Wherein, as most preferred technical scheme, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the aforementioned pharmaceutical compositions and tetravalence V is counted 1: 1 with vanadium.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of pentavalent V.Wherein, the content of vanadium of the inorganic acid salt of pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises proper inorganic acid, and wherein, said mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
The active component of aforementioned pharmaceutical compositions can be merely the inorganic acid salt of trivalent V.
Wherein, the active component of aforementioned pharmaceutical compositions can also be inorganic acid salt and the proper inorganic acid of trivalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of trivalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively trivalent V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively trivalent V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of trivalent V and the inorganic acid salt of tetravalence V.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of trivalent V, inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of trivalent V and tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical also can be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.Further, the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.5～1.5 in vanadium: 0.5～1.5.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is in vanadium more preferably 0.9～1.1: 0.9～1.1.The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V most preferably is 1: 1 in vanadium.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the inorganic acid salt of the V in the aforementioned pharmaceutical compositions is preferably sulfate, chlorate or phosphate.Further, when V was trivalent, the inorganic acid salt of V was preferably VCl
3, VOCl, V
2(SO
4)
3, VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3When V was tetravalence, the inorganic acid salt of V was preferably: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was preferably VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Inventor of the present invention is through discovering that the vanadium cation that contains in the pharmaceutical composition of the present invention is a main active.Therefore, the present invention also provides the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment osteoporosis, and this pharmaceutical composition comprises following active component: the cation that contains trivalent vanadium; Wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2+
Further, cation that contains trivalent vanadium and the VO in the aforementioned pharmaceutical compositions
2+Mol ratio be preferably 0.5～1.5: 0.5～1.5.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio more preferably 0.9～1.1: 0.9～1.1.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio most preferably be 1: 1.
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2+Wherein, VO
2 +Content is preferably cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.
Further, above-mentioned said active ingredient in pharmaceutical also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, L
I+And/or Ge
4+Wherein, K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can be for containing the cation of trivalent vanadium, and wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+And contain the cation of trivalent vanadium, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation and the VO that contains trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, contain the cation and the VO of trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation, the VO that contains trivalent vanadium
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, contain the cation of trivalent vanadium, VO
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Wherein, above-mentioned K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.Above-mentioned VO
2 +Content is preferably cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio be preferably 0.5～1.5: 0.5～1.5.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio more preferably 0.9～1.1: 0.9～1.1.Cation that contains trivalent vanadium and VO in the aforementioned pharmaceutical compositions
2+Mol ratio most preferably be 1: 1.
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Aforementioned pharmaceutical compositions can be the pharmaceutical dosage form of routine, and wherein, the dosage form of aforementioned pharmaceutical compositions is preferably transdermal formulation.Further, described transdermal formulation is preferably patch, varnish, liniment, aerosol, unguentum, solution or lotion.
When the dosage form of said medicine is lotion, when using, the patient can medicine of the present invention be added suitable quantity of water, and make the pH value of solution reach the acceptable faintly acid scope of human body; Soak then and use; General soak time 10～40min gets final product, and during immersion, soaks every day 1～6 time.
Do further description below in conjunction with the embodiment specific embodiments of the invention, therefore do not limit the present invention among the described scope of embodiments.
The preparation of embodiment 1 medicine
Medicine according to mol ratio preparation table 1.
The set of dispense of table 1 medicine is than (mol/L)
The drug prepared dosage form is a lotion, adds water during use and is mixed with pH value and is about and soaks behind 5.5 the solution or insert and wash use, and soak time is 10～40min.
The test of Test Example 1 Transdermal absorption
Experimental technique and step: the Transdermal absorption appearance TT-8 that adopts the just logical Science and Technology Ltd. in Tianjin to produce carries out percutaneous and absorbs diffusion experiment.Adopt Chengdu to reach the qualified adult wistar rat of large biological company limited quarantine, body weight 200～220g is as laboratory animal.With the cropping of rat elder generation, use 5wt%Na then
2The processing of losing hair or feathers of S solution, the depilation back was put to death rat on the 2nd day, and bark fetching is removed subcutaneus adipose tissue, carries out transdermal experiment.Press from both sides rat skin between diffusion cell lid and the diffusion cell during experiment, the diffusion cell lid adds test solution, and diffusion cell adds the PBS buffer of pH7.4, and buffer adopts ultra-pure water (containing vanadium less than 0.01ug/ml) preparation.After experiment finishes; Get buffer in the diffusion cell with 50ml volumetric flask standardize solution (volumetric flask in advance through ultra-pure water clean repeatedly); Detect content of vanadium in the PBS buffer (promptly absorb contain vanadium ion concentration) with ICP; Or other ion concentration (ion concentration that promptly absorbs), if the content of vanadium in the buffer or other ion concentration have raising, prove that then this ion can pass through Transdermal absorption.According to assay, the result is carried out the secondary experiment with the big test group of expection difference, if result of the test is then averaged as a result of with result of the test is approaching for the first time for the second time; If for the second time result of the test differs greatly with result of the test for the first time, then test for the third time, get two groups of the most close data result meansigma methodss as experimental result according to three experimental results.
Sulfate preparation with vanadium contains VO
+, VO
2+, VO
2 +, Fe
2+, Al
3+, K
+, Na
+, Se
4+, Li
+Isoionic solution is measured its percutaneous assimilation effect respectively with step according to the method described above.Specific as follows:
1, VO
+The percutaneous absorption data:
Cation in the testing liquid is VO
+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, Fe＜0.01ug/ml, Ge＜0.01ug/ml, Al＜0.01ug/ml, Ti＜0.01ug/ml, Se＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.Transdermal absorption time 15min, stock solution (being the testing liquid of not diluted) pH value is 1.5, the VO in the stock solution
+Concentration is counted 100g/L with vanadium, 40 ℃ of temperature, and the Transdermal absorption data of testing liquid are as shown in table 2, wherein, the VO of absorption
+Concentration is the concentration in vanadium.
(the VO of table 2 testing liquid
+) Transdermal absorption result
2, VO
+, Fe
2+, Al
3+, K
+, Na
+, Se
4+The percutaneous absorption data:
Cation in the testing liquid is VO
+, Fe
2+, Al
3+, K
+, Na
+, Se
4+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, Fe
2+＜0.01ug/ml, Al
3+＜0.01ug/ml, Se
4+＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 1.5, the VO in the stock solution
+Concentration is counted 100g/L with vanadium, Fe
2+, Al
3+, K
+, Na
+, Se
4+Concentration be respectively 1.5*10
-5Mol/L, 10
-5mOl/L, 1.5*10
-5Mol/L, 1.5*10
-5Mol/L, 10
-5Mol/L, 40 ℃ of temperature, the Transdermal absorption data of testing liquid are as shown in table 3, wherein, the VO of absorption
+Concentration is the concentration in vanadium, and the ion concentration that absorbs described in the table is the ion concentration that increases in the buffer, down together.
(the VO of table 3 testing liquid
+, Fe
2+, Al
3+, K
+, Na
+, Se
4+) Transdermal absorption result
3, VO
+, VO
2+(mol ratio 1: 1) percutaneous absorption data
Cation in the testing liquid is VO
+, VO
2+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 1.0, the VO in the stock solution
+, VO
2+Total concentration is counted 100g/L with vanadium, 40 ℃ of temperature, and the Transdermal absorption data of testing liquid are as shown in table 4, wherein, the VO of absorption
+, VO
2+Concentration is the total concentration in vanadium.
(the VO of table 4 testing liquid
+, VO
2+) Transdermal absorption result
4, VO
+, VO
2+(VO
+, VO
2+Mol ratio 1: 1), Fe
2+, K
+, Na
+, Se
4+Cation in the percutaneous absorption data testing liquid is VO
+, VO
2+, Fe
2+, K
+, Na
+, Se
4+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, Fe
2+＜0.01ug/ml, Se
4+＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 15min, stock solution (being the testing liquid of not diluted) pH value is 1.0, the VO in the stock solution
+, VO
2+Total concentration is counted 100g/L with vanadium, Fe
2+, K
+, Na
+, Se
4+Concentration be respectively 1.5*10
-5Mol/L, 1.5*10
-5Mol/L, 1.5*10
-5Mol/L, 10
-5Mol/L, 40 ℃ of temperature, the Transdermal absorption data of testing liquid are as shown in table 5.
(the VO of table 5 testing liquid
+, VO
2+, Fe
2+, K
+, Na
+, Se
4+) Transdermal absorption result
5, VO
+, VO
2+, VO
2 +According to 100: 100: 3 proportioning liquid of mol ratio percutaneous data:
Cation in the testing liquid is VO
+, VO
2+, VO
2 +, anion is SO
4 2-PBS buffer V＜0.01ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 1.5, the VO in the stock solution
+, VO
2+, VO
2 +Total concentration is counted 100g/L with vanadium, 40 ℃ of temperature, and the Transdermal absorption data of testing liquid are as shown in table 6.
(the VO of table 6 testing liquid
+, VO
2+, VO
2 +) Transdermal absorption result
6, VO
+, VO
2+, VO
2 +, Fe
2+, K
+, Na
+Percutaneous absorption data (VO
+, VO
2+, VO
2 +Mol ratio be 150: 100: 1)
Cation in the testing liquid is VO
+, VO
2+, VO
2 +, Fe
2+, K
+, Na
+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, Fe＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 1.0, the VO in the stock solution
+, VO
2+, VO
2 +Total concentration is counted 100g/L with vanadium, Fe
2+, K
+, Na
+Concentration be respectively 10
-5Mol/L, 10
-5Mol/L, 10
-5Mol/L, 40 ℃ of temperature, the Transdermal absorption data of testing liquid are as shown in table 7.
(the VO of table 7 testing liquid
+, VO
2+, VO
2 +, Fe
2+, K
+, Na
+) Transdermal absorption result
Can find out that from table 2～7 the Transdermal absorption effect of medicine of the present invention is better.
Test Example 2 adopts Drug therapy osteoporosis of the present invention
Yin * *, man, 63 years old.The pain of walking appearred in right foot in 2006, the aggravation of movable back.To hospital diagnosis is osteoporosis, and photo is found right whole calcanean spur.The doctor infers that left side foot can form new bony spur after 1 year.The middle pain the most of pain, especially heel on foot appearred in patient left side foot in 2007, and photo finds that bony spur appears in left side foot.The patient successively carried out twice small needle knife operation in 2007 to 2009, and the operation second time is carried out in bony spur recurrence later six months of performing the operation for the first time again.Owing to the work reason, needs of patients is walked about for a long time, and in JIUYUE, 2009, pain appearred again in patient's foot, and the doctor advises that the patient quits work, and expectant treatment is main with rest, otherwise possibly cause the both feet walking of can't standing.In October, 2009, the patient uses medicine of the present invention (embodiment 1, numbering 11) foot bath, each 30min, every day 2 times, use 3 months continuously after, can normally walk, foot pain obviously alleviates.Bring into use medicine of the present invention (embodiment 1, numbering 6) foot bath in January, 2010, each 30min, every day 2 times, use 3 months continuously after, complete obiterations such as the foot pain that bony spur causes, walking disorder, operate as normal fully.
Test Example 3 adopts Drug therapy osteoporosis of the present invention
Liao * *, woman, patient, woman, 49 years old.The gonalgia appears in 2009 beginning of the years, increases the weight of to accompany difficulty.The gonalgia appears in patient's readme menopause before 1 year after the menopause, occur 1 side knee joint symptom such as feel like jelly suddenly in the time of upstairs.Hospital's auxiliary examination: three big conventional, erythrocyte sedimentation rate and hepatic and renal function, vim and vigour are all normal.X ray examination knee joint osteoporosis, hospital diagnosis is the degeneration osteoporosis.In January, 2010, the patient used medicine of the present invention (embodiment 1, numbering 1) foot bath, each 30min, every day 1 time, use 3 months continuously after, patient's gonalgia is alleviated, long-term flank pain also take a favorable turn.In April, 2010, the patient uses medicine of the present invention (embodiment 1, numbering 4) foot bath, and each 30min used for 3 weeks every day 1 time continuously, gonalgia complete obiteration, and the photo result shows the osteoporosis recovery from illness.
Claims (31)
1. the pharmaceutical composition purposes in the medicine of preparation treatment osteoporosis, wherein, described pharmaceutical composition comprises the inorganic acid salt of following active component: trivalent V.
2. purposes according to claim 1 is characterized in that: said active ingredient in pharmaceutical also comprises the inorganic acid salt of tetravalence V.
3. purposes according to claim 2 is characterized in that: the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V counts 0.5～1.5 with vanadium: 0.5～1.5; The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V preferably counts 0.9～1.1 with vanadium: 0.9～1.1; The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is more preferably counted 1: 1 with vanadium.
4. according to each described purposes of claim 1～3, it is characterized in that: said active ingredient in pharmaceutical also comprises the inorganic acid salt of pentavalent V.
5. purposes according to claim 4 is characterized in that: the content of vanadium of the inorganic acid salt of pentavalent V be trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.
6. according to each described purposes of claim 1～5, it is characterized in that: said active ingredient in pharmaceutical also comprises proper inorganic acid, and wherein, said mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
7. according to each described purposes of claim 1～6, it is characterized in that: said active ingredient in pharmaceutical also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.
8. purposes according to claim 7 is characterized in that: the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
9. purposes according to claim 1 is characterized in that: said active ingredient in pharmaceutical is the inorganic acid salt of trivalent V; Or
Said active ingredient in pharmaceutical is inorganic acid salt and the proper inorganic acid of trivalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of trivalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
10. purposes according to claim 9 is characterized in that: the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively trivalent V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
11. purposes according to claim 1 is characterized in that: said active ingredient in pharmaceutical is the inorganic acid salt of trivalent V and the inorganic acid salt of tetravalence V; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of trivalent V, inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of trivalent V and tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
12. purposes according to claim 11 is characterized in that: the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
13. purposes according to claim 1 is characterized in that: said active ingredient in pharmaceutical is the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of trivalent V, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
14. purposes according to claim 13 is characterized in that: the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
15., it is characterized in that according to claim 13 or 14 described purposes: the content of vanadium of the inorganic acid salt of described pentavalent V be trivalent V inorganic acid salt and tetravalence V the total vanadium mole of inorganic acid salt 0.5%～5%.
16. according to each described purposes of claim 11～15, it is characterized in that: the mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V counts 0.5～1.5 with vanadium: 0.5～1.5; The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is preferably 0.9～1.1 in vanadium: 0.9～1.1; The mol ratio of the inorganic acid salt of the inorganic acid salt of the trivalent V in the said pharmaceutical composition and tetravalence V is most preferably counted 1: 1 with vanadium.
17. according to each described purposes of claim 1～16, it is characterized in that: the inorganic acid salt of described trivalent V is sulfate, chlorate or the phosphate of trivalent V; The inorganic acid salt of described tetravalence V is sulfate, chlorate or the phosphate of tetravalence V; The inorganic acid salt of described pentavalent V is sulfate, chlorate or the phosphate of pentavalent V.
18. purposes according to claim 17 is characterized in that: when V was trivalent, the inorganic acid salt of V was VCl
3, VOCl, V
2(SO
4)
3, VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3When V was tetravalence, the inorganic acid salt of V was: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
19. the purposes of a pharmaceutical composition in the medicine of preparation treatment osteoporosis is characterized in that described pharmaceutical composition comprises following active component: the cation that contains trivalent vanadium; Wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O) 6]
3+
20. purposes according to claim 19 is characterized in that: said active ingredient in pharmaceutical also comprises VO
2+
21. purposes according to claim 20 is characterized in that: cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio be 0.5～1.5: 0.5～1.5; Cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio be preferably 0.9～1.1: 0.9～1.1; Cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio most preferably be 1: 1.
22. according to each described purposes of claim 19～21, it is characterized in that: said active ingredient in pharmaceutical also comprises VO
2 +
23. purposes according to claim 22 is characterized in that: VO
2 +Content is cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.
24. according to each described purposes of claim 19～23, it is characterized in that: said active ingredient in pharmaceutical also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+
25. purposes according to claim 24 is characterized in that: K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content be respectively V integral molar quantity 10
-6～10
-5Doubly.
26. purposes according to claim 19 is characterized in that: said active ingredient in pharmaceutical is the cation that contains trivalent vanadium, and wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+And contain the cation of trivalent vanadium, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation and the VO that contains trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, contain the cation and the VO of trivalent vanadium
2+, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is cation, the VO that contains trivalent vanadium
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, contain the cation of trivalent vanadium, VO
2+And VO
2 +, wherein, the described cation that contains trivalent vanadium is VO
+Or [V (H
2O)
6]
3+
27. purposes according to claim 26 is characterized in that: described K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content be respectively V integral molar quantity 10
-6～10
-5Doubly.
28., it is characterized in that: described VO according to claim 26 or 27 described purposes
2 +Content is cation and the VO that contains trivalent vanadium
2+0.5%～5% of total vanadium mole.
29. according to each described purposes of claim 26～28, it is characterized in that: cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio be 0.5～1.5: 0.5～1.5; Cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio be preferably 0.9～1.1: 0.9～1.1; Cation that contains trivalent vanadium and VO in the said pharmaceutical composition
2+Mol ratio most preferably be 1: 1.
30. according to each described purposes of claim 1～29, it is characterized in that: the dosage form of said pharmaceutical composition is a transdermal formulation.
31. purposes according to claim 30 is characterized in that: described transdermal formulation is patch, varnish, liniment, aerosol, unguentum, solution or lotion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101251677A CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010208132.5 | 2010-06-24 | ||
| CN201010208132 | 2010-06-24 | ||
| CN201010216341 | 2010-07-02 | ||
| CN201010216341.4 | 2010-07-02 | ||
| CN2011101251677A CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102309506A true CN102309506A (en) | 2012-01-11 |
Family
ID=43450946
Family Applications (20)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
| CN2010105414518A Active CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN 201110125426 Pending CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101251677A Pending CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
Family Applications Before (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
| CN2010105414518A Active CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN 201110125426 Pending CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (20) | CN101947238B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104398788A (en) * | 2014-11-25 | 2015-03-11 | 孙莉莉 | Traditional Chinese medicine electuary for treating insomnia and preparation method for traditional Chinese medicine electuary |
| CN106692546A (en) * | 2015-11-14 | 2017-05-24 | 张立 | Medicinal liquor for treating rheumatism and ostealgia |
| CN107375254A (en) * | 2017-08-30 | 2017-11-24 | 李炜 | A kind of external plaster and its application method for being used to treat diabetes |
| CN107485706A (en) * | 2017-09-01 | 2017-12-19 | 仲崇允 | A kind of Chinese medicine for treating breast cancer |
| CN114177196A (en) | 2020-09-14 | 2022-03-15 | 湖南方升泰医药科技有限公司 | Vanadium compounds for use in methods of treating pain |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843481A (en) * | 1994-01-18 | 1998-12-01 | Mount Sinai Hospital Corporation | Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof |
| IL121748A0 (en) * | 1997-09-11 | 1998-02-22 | Yeda Res & Dev | Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them |
| CN1118243C (en) * | 1999-12-17 | 2003-08-20 | 王将克 | Nutritive soybean-pumpkin powder |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| CN1178946C (en) * | 2000-11-28 | 2004-12-08 | 昆明贵金属研究所 | Vanadium compound and its preparing process and usage |
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CN1179659C (en) * | 2002-05-20 | 2004-12-15 | 郑军武 | Prep. of vanadium-enriched nutrient extender |
| CN1413727A (en) * | 2002-09-09 | 2003-04-30 | 凌一峰 | Composite medicine for radical curing AIDS |
| CN1187091C (en) * | 2002-09-24 | 2005-02-02 | 浙江大学 | Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage |
| CN1460472A (en) * | 2003-06-06 | 2003-12-10 | 乐益 | Biquanide vanadium complex plaster preparation for curing diabetes and its application |
| FI121915B (en) * | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Composition for the treatment of psoriasis |
| US20070066682A1 (en) * | 2005-07-01 | 2007-03-22 | Exposito Miriam R | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus |
| WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
| DE602007006641D1 (en) * | 2006-02-21 | 2010-07-01 | Astrum Therapeutics Pty Ltd | COMPOSITIONS FOR REDUCING THE BLOOD GLUCOSE MIRROR AND TREATING DIABETES |
| CN1846711A (en) * | 2006-04-25 | 2006-10-18 | 苟仕金 | Balanced solution with trace elements for extracorporeal culture of bezoar and its prepn process |
| CN101033239A (en) * | 2007-01-31 | 2007-09-12 | 辽宁师范大学 | Preparation and structure of novel para-insulin pharmaceutical model compound |
| CN101362684A (en) * | 2008-07-23 | 2009-02-11 | 郑德龙 | Solution containing vanadium oxalate and preparation method thereof |
-
2010
- 2010-09-30 CN CN2010102980383A patent/CN101947238B/en active Active
- 2010-09-30 CN CN2010102988277A patent/CN101953846B/en active Active
- 2010-11-12 CN CN2010105415845A patent/CN101961347B/en active Active
- 2010-11-12 CN CN2010105414518A patent/CN101978965B/en active Active
-
2011
- 2011-05-16 CN CN2011101250956A patent/CN102309505A/en active Pending
- 2011-05-16 CN CN2011101255659A patent/CN102309517A/en active Pending
- 2011-05-16 CN CN2011101254196A patent/CN102309514A/en active Pending
- 2011-05-16 CN CN2011101258093A patent/CN102309518A/en active Pending
- 2011-05-16 CN CN201110125808.9A patent/CN102302511B/en active Active
- 2011-05-16 CN CN2011101253672A patent/CN102309511A/en active Pending
- 2011-05-16 CN CN2011101252951A patent/CN102309509A/en active Pending
- 2011-05-16 CN CN 201110125426 patent/CN102309516A/en active Pending
- 2011-05-16 CN CN2011101254209A patent/CN102309515A/en active Pending
- 2011-05-16 CN CN2011101251677A patent/CN102309506A/en active Pending
- 2011-05-16 CN CN2011101254105A patent/CN102309512A/en active Pending
- 2011-05-16 CN CN 201110125280 patent/CN102309508A/en active Pending
- 2011-05-16 CN CN2011101254177A patent/CN102309513A/en active Pending
- 2011-05-16 CN CN201110125431.7A patent/CN102302510B/en active Active
- 2011-05-16 CN CN2011101253009A patent/CN102309510A/en active Pending
- 2011-05-16 CN CN2011101251785A patent/CN102309507A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 《中国营养学会第九次全国营养学术会议论文摘要汇编》 20041010 茅小燕等 钒在糖尿病、骨质疏松治疗中的作用与开发利用 118-119 1-31 , * |
| 申小英: "钒对骨质疏松的作用及其机制", 《国外医学 内分泌学分册》 * |
| 颜晓平等: "钒的生物学作用研究进展", 《上海交通大学学报（农业科学版）》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309513A (en) | 2012-01-11 |
| CN102309505A (en) | 2012-01-11 |
| CN101947238A (en) | 2011-01-19 |
| CN102302510A (en) | 2012-01-04 |
| CN102309516A (en) | 2012-01-11 |
| CN101961347B (en) | 2011-12-21 |
| CN102309518A (en) | 2012-01-11 |
| CN102309512A (en) | 2012-01-11 |
| CN102309509A (en) | 2012-01-11 |
| CN102309517A (en) | 2012-01-11 |
| CN101953846B (en) | 2011-12-28 |
| CN102309507A (en) | 2012-01-11 |
| CN102309510A (en) | 2012-01-11 |
| CN102302511B (en) | 2015-06-03 |
| CN102309508A (en) | 2012-01-11 |
| CN101978965B (en) | 2011-12-28 |
| CN101961347A (en) | 2011-02-02 |
| CN102309514A (en) | 2012-01-11 |
| CN102302510B (en) | 2014-04-23 |
| CN102302511A (en) | 2012-01-04 |
| CN101953846A (en) | 2011-01-26 |
| CN101947238B (en) | 2011-12-21 |
| CN102309511A (en) | 2012-01-11 |
| CN101978965A (en) | 2011-02-23 |
| CN102309515A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102309506A (en) | Application of drug composition in preparation of drugs for treating osteoporosis | |
| WILDER et al. | Intake of potassium, an important consideration in Addison's disease: a metabolic study | |
| CN103908491A (en) | Composition for treating beriberi and foot stench, and preparation method thereof | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| CN102100735B (en) | Medicinal composition for treating skin diseases | |
| CN101574465B (en) | Special acne removal traditional Chinese medicine tincture for ladies | |
| CN108498535A (en) | A kind of povidone iodine pharmaceutical composition and its preparation method and application for treating skin and mucosa infection | |
| CN101601768B (en) | Chinese medicinal composition for treating tinea pedis and scabies and preparation method thereof | |
| CN103432049B (en) | Composition with deodorization function | |
| Arya et al. | Treating diabetes mellitus with vanadium salts–a future prospectus: a review | |
| CN103961372B (en) | A kind of neutral phosphate pulvis | |
| Adinoyi et al. | Role of Moringa oleifera on electrolytes levels and cardiovascular function in human | |
| CN104840404A (en) | Cosmetic with deodorization function and preparation method thereof | |
| Whitford et al. | Fluoride absorption: independence from plasma fluoride levels | |
| CN108465031A (en) | A kind of Chinese medicine composition and preparation method thereof for treating osteoporosis | |
| RU2315611C1 (en) | Balneological active additive for balneological bath agent (variants) and balneological bath agent based on the same | |
| CN105534998A (en) | External preparation for treating skin itch caused by dry skin and preparing method of external preparation | |
| CN102151285A (en) | Neutral calcium supplement preparation | |
| CN101972273A (en) | Application of medicine in preparing medicines for treating diabetes mellitus | |
| WO2011160444A1 (en) | Pharmaceutical composition comprising vanadium and its use | |
| Blumgarten | Materia medica for nurses | |
| CN102210697B (en) | Medicine composition for treating metabolic bone diseases | |
| Shin | Study on Hydrophobic Drug-Soluble Carrier Coprecipitates (III)-Diuretic Effects of Furosemide-PVP Coprecipitate | |
| CN1302609A (en) | Phosphonate medicine for treating osteoporosis and bone cancer transfer | |
| CN103191149A (en) | Medicinal composition for treating osteoporosis, and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120111 |